Mylan EpiPen Price Increases 550% in Nine Years, CEO Heather Bresch Testifies Before Congress
In August 2016, Mylan CEO Heather Bresch faced intense scrutiny when it was revealed that EpiPen prices had increased from approximately $103 in 2007 to over $608 by 2016—a nearly 550% price increase for a life-saving allergy treatment. The scandal exposed pharmaceutical price gouging, the failure …
Mylan
Heather Bresch
U.S. Congress
healthcare
pharmaceutical-price-gouging
regulatory-capture
corruption
corporate-crime
Read more →